[8-K] Anteris Technologies Global Corp. Reports Material Event

Rhea-AI Filing Summary

Anteris Technologies Global Corp. reported that it has presented new clinical information on its DurAVR^® Transcatheter Heart Valve (THV). The company issued an ASX announcement on November 16, 2025 (November 17, 2025 AEDT) and a press release on November 17, 2025 summarizing 30-day clinical outcomes in one hundred severe aortic stenosis patients with small aortic annuli treated with DurAVR THV. This information is being furnished to regulators rather than formally filed, meaning it is shared for transparency but does not carry the same legal status as filed financial statements.

false000201151400020115142025-11-172025-11-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2025

Anteris Technologies Global Corp.

(Exact name of registrant as specified in its charter)

Delaware		001-42437		99-1407174
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Toowong Tower, Level 3, Suite 302 9 Sherwood Road Toowong, QLD Australia		4066
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: +61 7 3152 3200

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		AVR		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure

On November 16, 2025 (November 17, 2025 AEDT), Anteris Technologies Global Corp. (the “Company”) issued an ASX Announcement and on November 17, 2025 issued a press release presenting the 30-day clinical outcomes for the DurAVR^® Transcatheter Heart Valve (THV) in one hundred severe aortic stenosis patients with small aortic annuli.

The information in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, unless such subsequent filing specifically references this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.		Description
99.1		ASX announcement: Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Anteris Technologies Global Corp.
Date: November 17, 2025
	By:	/s/ Wayne Paterson
	Name:	Wayne Paterson
	Title:	Chief Executive Officer

FAQ

What did Anteris Technologies Global Corp. (AVR) announce in this 8-K?

Anteris Technologies Global Corp. furnished an ASX announcement and a press release presenting 30-day clinical outcomes for its DurAVR^® Transcatheter Heart Valve in one hundred severe aortic stenosis patients with small aortic annuli.

Which product is highlighted in Anteris Technologies (AVR)'s latest 8-K filing?

The filing highlights clinical outcomes for the DurAVR^® Transcatheter Heart Valve (THV), used to treat severe aortic stenosis in patients with small aortic annuli.

How many patients were included in the DurAVR THV 30-day outcomes reported by AVR?

The 30-day clinical outcomes reported by Anteris Technologies covered one hundred severe aortic stenosis patients with small aortic annuli treated with the DurAVR^® THV.

Are the DurAVR THV clinical results in AVR's 8-K considered filed financial information?

No. The company states that the information, including the attached exhibit, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act or incorporated into Securities Act or Exchange Act filings unless specifically referenced later.

What exhibit is attached to Anteris Technologies (AVR)'s 8-K about DurAVR THV?

The attached exhibit is 99.1, titled “ASX announcement: Anteris Technologies Presents Data from 100 DurAVR^® THV Patients at PCR London Valves,” along with the cover page interactive data file embedded in the Inline XBRL document.

On which exchange is Anteris Technologies Global Corp. (AVR) listed?

Anteris Technologies Global Corp. lists its common stock, par value $0.0001 per share, on The Nasdaq Global Market under the trading symbol AVR.